rosiglitazone has been researched along with Encephalopathy, Toxic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Coelho, MS; Duarte, DB; Neves, FAR; Oliveira, HR | 1 |
| Chen, L; Huang, W; Park, M; Toborek, M; Zhang, B | 1 |
| Chaudhary, T; Kumar, A; Mishra, J | 1 |
| Cinci, L; Di Cesare Mannelli, L; Failli, P; Ghelardini, C; Micheli, L; Zanardelli, M | 1 |
| Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S | 1 |
| Chen, K; Shen, X; Zhao, Y | 1 |
6 other study(ies) available for rosiglitazone and Encephalopathy, Toxic
| Article | Year |
|---|---|
Cisplatin-induced changes in calcitonin gene-related peptide or TNF-α release in rat dorsal root ganglia in vitro model of neurotoxicity are not reverted by rosiglitazone.
Topics: Animals; Calcitonin Gene-Related Peptide; Cisplatin; Ganglia, Spinal; Hypoglycemic Agents; Neurotoxicity Syndromes; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2022 |
PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Cell Count; Fenofibrate; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Neurons; Neurotoxicity Syndromes; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; tat Gene Products, Human Immunodeficiency Virus; Thiazolidinediones; Tight Junction Proteins | 2014 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Huntington Disease; Male; Maze Learning; Motor Activity; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxicity Syndromes; PPAR gamma; Quinolinic Acid; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Valproic Acid | 2014 |
Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.
Topics: Animals; Antineoplastic Agents; Antioxidants; Astrocytes; Catalase; Cell Line, Tumor; Cells, Cultured; Ganglia, Spinal; HT29 Cells; Humans; Male; Mitochondria; Neuralgia; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxidation-Reduction; Peroxisomes; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Spinal Cord; Thiazolidinediones | 2014 |
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones | 2015 |
Environmental Enrichment Attenuated Sevoflurane-Induced Neurotoxicity through the PPAR-γ Signaling Pathway.
Topics: Animals; Apoptosis; Cognition Disorders; Down-Regulation; Environment; Male; Memory Disorders; Methyl Ethers; Mice, Inbred C57BL; Neurogenesis; Neurons; Neurotoxicity Syndromes; PPAR gamma; Rosiglitazone; Sevoflurane; Signal Transduction; Thiazolidinediones | 2015 |